Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by (1,051)

Items 901–1,000 of 1,051

1. Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
   Chung‐Han Lee, Roman Yelensky, Karin U. Jooss, Timothy An-thy Chan · 2018 · Trends in Immunology
2. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
   Qinghua Wang, Meiling Li, Meng Yang, Yichen Yang, Fengju Song, Wei Zhang, Xiangchun Li, Kexin Chen · 2020 · Aging
3. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
   Chang Gon Kim, Joong Bae Ahn, Minkyu Jung, Seung‐Hoon Beom, Chan Kim, Joo Hoon Kim, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Nam Kyu Kim et al. · 2016 · British Journal of Cancer
4. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
   Ludmila Danilova, Hao Wang, Joel Chaim Sunshine, Genevieve J. Kaunitz, Tricia R. Cottrell, Haiying Xu, Jessica Esandrio, Robert A. Anders, Leslie Cope, Drew M. Pardoll et al. · 2016 · Proceedings of the National Academy of Sciences
5. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
   Subudhi, Sumit K., Vence, Luis, Zhao, Hao, Blando, Jorge, Yadav, Shalini S., Xiong, Qing, Reuben, Alexandre, Aparicio, Ana, Corn, Paul G., Chapin, Brian F. et al. · 2020 · Science Translational Medicine
6. Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer
   Sceneay, Jaclyn, Goreczny, Gregory J., Wilson, Kristin, Morrow, Sara, DeCristo, Molly J., Ubellacker, Jessalyn M., Qin, Yuanbo, Laszewski, Tyler, Stover, Daniel G., Barrera, Victor et al. · 2019 · Cancer Discovery
7. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
   Grit Sophie Herter-Sprie, Shohei Koyama, Houari Korideck, Josephine Hai, Jiehui Deng, Yvonne Y. Li, Kevin A. Buczkowski, Aaron K. Grant, Soumya Ullas, Kevin Rhee et al. · 2016 · JCI Insight
8. Advances in immunotherapy for melanoma
   Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
9. Inactivation of Capicua drives cancer metastasis
   Ross A. Okimoto, Frank Breitenbuecher, Victor R. Olivas, Wei Wu, Beatrice Gini, Matan Hofree, Saurabh Asthana, Gorjan Hrustanovic, Jennifer Flanagan, Asmin Tulpule et al. · 2016 · Nature Genetics
10. Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
    Aline Talhouk, Heather Derocher, Pascal Schmidt, Samuel C. Y. Leung, Katy Milne, C. Blake Gilks, Michael S. Anglesio, Brad H. Nelson, Jessica Nell McAlpine · 2019 · Clinical Cancer Research
11. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
    Markus W. Loeffler, Christopher Mohr, Leon Bichmann, Lena Katharina Freudenmann, Mathias Walzer, Christopher Schroeder, Nico Trautwein, Franz J. Hilke, Raphael S. Zinser, Lena Mühlenbruch et al. · 2019 · Genome Medicine
12. Applications of single-cell and bulk RNA sequencing in onco-immunology
    Maria Kuksin, Daphné Morel, Marine Aglave, François‐Xavier Danlos, Aurélien Marabelle, Andrei Y. Zinovyev, Daniel Gautheret, Loïc Verlingue · 2021 · European Journal of Cancer
13. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape
    Hawazin Faruki, Gregory M. Mayhew, Jonathan Stuart Serody, David Neil Hayes, Charles M. Perou, Myla Lai-Goldman · 2017 · Journal of Thoracic Oncology
14. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
    Michael C. Haffner, Güneş Güner, Diana Taheri, George Jabboure Netto, Doreen N. Palsgrove, Qizhi Zheng, Liana B. Guedes, Kunhwa Kim, Harrison Kwei Tsai, David Esopi et al. · 2018 · American Journal Of Pathology
15. Optimizing panel-based tumor mutational burden (TMB) measurement
    Jan Budczies, Michael Allgäuer, Kevin Litchfield, Eugen Rempel, Petros Christopoulos, Daniel N. Kazdal, Volker Endris, Michael Thomas, Stefan Fröhling, Solange Peters et al. · 2019 · Annals of Oncology
16. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy
    Linda Quatrini, Francesca Romana Mariotti, Enrico Munari, Nicola Tumino, Paola Vacca, Lorenzo Moretta · 2020 · Cancers
17. Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
    Juanjuan Yuan, Ting Cai, Xiaojun Zheng, Yangzi Ren, Jingwen Qi, Xiaofei Lü, Huihui Chen, Huizhen Lin, Zijie Chen, Mengnan Liu et al. · 2021 · Protein & Cell
18. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
    Itziar Otano, Alvaro Conrado Ucero, Jon Zugazagoitia, Luis G Paz-Ares · 2023 · Nature Reviews Clinical Oncology
19. Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs
    Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Rui Manuel Reis, Letícia Ferro Leal · 2023 · International Journal of Molecular Sciences
20. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
    Amy Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart, Melissa Lynne Johnson, Brian S. Henick, Chih‐Yi Liao, Amit Mahipal, Ardaman P. Shergill, Alexander I. Spira et al. · 2024 · Nature Medicine
21. Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors
    Zinal S. Chheda, Rajesh Kumar Sharma, Venkatakrishna Rao Jala, Andrew David Luster, Bodduluri Haribabu · 2016 · The Journal of Immunology
22. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
    Jie Bai, Zhitao Gao, Xiang Li, Liang Dong, Weidong Han, Jing Nie · 2017 · Oncotarget
23. Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information
    Sangwoo Kim, Eun‐Young Kim, E. Kim, M. Lee, E.-C. Shin, Soonmyung Paik, Sangwoo Kim · 2018 · Annals of Oncology
24. Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
    Qingzhu Jia, Jun Wang, Ning He, Ji He, Bo Zhu · 2019 · JCI Insight
25. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group
    Leticia De Mattos‐Arruda, Miguél Vázquez, Francesca Finotello, Rosalba Lepore, E. Porta, Jasreet Hundal, Pep Amengual-Rigo, Charlotte K.Y. Ng, Alfonso Valencia, Jorge Carrillo et al. · 2020 · Annals of Oncology
26. The status of tumor mutational burden and immunotherapy
    Valsamo Anagnostou, Alberto Bardelli, Timothy An-thy Chan, Samra Turajlic · 2022 · Nature Cancer
27. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
    Amos Kirilovsky, Florence Marliot, Carine El Sissy, Nacilla Haicheur, Jérôme Galon, Franck Pagès · 2016 · International Immunology
28. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
    Yoon Jin Cha, Hye Ryun Kim, Chang Young Lee, Byoung Chul Cho, Hyo Sup Shim · 2016 · Lung Cancer
29. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
    Steffen Böhm, Anne Montfort, Oliver M.T. Pearce, Joanne H. Topping, Probir Chakravarty, Gemma L.A. Everitt, Andrew James Clear, Jackie R. McDermott, Darren P. Ennis, Thomas Dowe et al. · 2016 · Clinical Cancer Research
30. T-cell receptor-engineered T cells for cancer treatment: current status and future directions
    Ping Yü, Chaojun Liu, Yi Zhang · 2017 · Protein & Cell
31. Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer
    Sara Bobisse, Raphaël Genolet, Annalisa Roberti, Janos Laszlo Tanyi, Julien Racle, Brian J. Stevenson, Christian Iseli, Alexandra Michel, Marie‐Aude Le Bitoux, Philippe Guillaume et al. · 2018 · Nature Communications
32. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
    Han Yao, Huanbin Wang, Chushu Li, Jing‐Yuan Fang, Jie Xu · 2018 · Frontiers in Immunology
33. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Jong Yeob Kim, Andreas Kronbichler, Michael Eisenhut, Sung Hwi Hong, Hans J. van der Vliet, Jeonghyun Kang, Jae Il Shin, Gabriele Gamerith · 2019 · Cancers
34. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
    Andreas Nicholas Saltos, Michael Rahman Shafique, Alberto Chiappori · 2020 · Frontiers in Oncology
35. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
    Solange Peters, Keith M. Kerr, Rolf Arno Stahel · 2017 · Cancer Treatment Reviews
36. Update on Immunohistochemistry for the Diagnosis of Lung Cancer
    Kentaro Inamura · 2018 · Cancers
37. PD-L1 expression testing in non-small cell lung cancer
    Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemı́ Reguart · 2018 · Therapeutic Advances in Medical Oncology
38. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
    Venkatesh Sivanandam, Christopher James LaRocca, Nanhai G. Chen, Yuman Fong, Susanne Gray Warner · 2019 · Molecular Therapy — Oncolytics
39. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
    Marine Leclerc, Elodie Voilin, Gwendoline Gros, Stéphanie Corgnac, Vincent de Montpréville, Pierre Validire, Georges Bismuth, Fathia Mami‐Chouaib · 2019 · Nature Communications
40. Development of Peptide-Based Vaccines for Cancer
    Noraini Abd-Aziz, Chit Laa Poh · 2022 · Journal of Oncology
41. Cancer immune contexture and immunotherapy
    Étienne Becht, Nicolás A. Giraldo, Marie‐Caroline Dieu‐Nosjean, Catherine Sautès‐Fridman, Wolf H. Fridman · 2015 · Current Opinion in Immunology
42. Immune checkpoint inhibition in ovarian cancer
    Junzo Hamanishi, Masaki Mandai, Ikuo Konishi · 2016 · International Immunology
43. Targeting immune checkpoints in breast cancer: an update of early results
    Cinzia Solinas, Andrea Gombos, Sofiya Latifyan, Martine J Piccart, Marleen Kok, Laurence Buisseret · 2017 · ESMO Open
44. Trial watch: Peptide-based vaccines in anticancer therapy
    Lucillia Bezu, Oliver Kepp, Giulia Cerrato, Jonathan G. Pol, Jitka Palich Fucikova, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2018 · OncoImmunology
45. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
    Alena Gros, Eric Tran, Maria R. Parkhurst, Sadia Ilyas, Anna Pasetto, Eric M. Groh, Paul F. Robbins, Rami Yossef, Andrea García-Garijo, Carlos Alberto Fajardo et al. · 2019 · Journal of Clinical Investigation
46. MSIsensor-Pro: Fast, Accurate, and Matched-Normal-Sample-Free Detection of Microsatellite Instability
    Peng Jia, Xiaofei Yang, Li Guo, Bowen Liu, Jiadong Lin, Hao Liang, Jianyong Sun, Chengsheng Zhang, Kai Ye · 2020 · Genomics Proteomics & Bioinformatics
47. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
    Changxia Shao, Gerald Li, Lingkang Huang, Scott Knowles Pruitt, Emily H. Castellanos, Garrett Michael Frampton, Kenneth Robert Carson, Tamara Snow, Gaurav Singal, David A. Fabrizio et al. · 2020 · JAMA Network Open
48. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
    Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou� Huang, Mohammad Reza Karimzadeh, Amir Abbas Momtazi‐Borojeni, Sheng Chen · 2021 · Journal for ImmunoTherapy of Cancer
49. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
    Joao V. Alessi, Biagio Ricciuti, Liam Flinn Spurr, Hersh V. Gupta, Yvonne Y. Li, Carolyn Glass, Mizuki Nishino, Andrew D. Cherniack, James R. Lindsay, Bijaya Sharma et al. · 2021 · Journal of Thoracic Oncology
50. Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function
    Joshua R. Veatch, Sylvia M. Lee, Carolyn Shasha, Naina Singhi, Julia L. Szeto, Ata S. Moshiri, Teresa S. Kim, Kimberly S. Smythe, Paul Kong, Matthew Fitzgibbon et al. · 2022 · Cancer Cell
51. Decision support systems for personalized and participative radiation oncology
    Philippe Lambin, Jaap D. Zindler, Ben G. L. Vanneste, Lien Van De Voorde, Daniëlle B. P. Eekers, Inge Compter, Kranthi M. Panth, Jurgen Peerlings, Ruben T. H. M. Larue, Timo M. Deist et al. · 2016 · Advanced Drug Delivery Reviews
52. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
    Takahiro Karasaki, Kazuhiro Nagayama, Hideki Kuwano, Jun‐ichi Nitadori, Masaaki Sato, Masaki Anraku, Akihiro Hosoi, Hirokazu Matsushita, Yasuyuki Morishita, Kosuke Kashiwabara et al. · 2017 · Journal of Thoracic Oncology
53. Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment
    Frederick S. Varn, Yue Wang, David W. Mullins, Steven Fiering, Chao Cheng · 2017 · Cancer Research
54. Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis
    Monica Khunger, Adrián Vladimir Hernández, Vinay Pasupuleti, Sagar Rakshit, Nathan A. Pennell, James P. Stevenson, Sanjay Mukhopadhyay, Kurt Alex Schalper, Vamsidhar Velcheti · 2017 · JCO Precision Oncology
55. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
    Ross Andrew Soo, Sun Min Lim, Nicholas L. X. Syn, Rebecca Siew Yan Teng, Richie Soong, Tony S.K. Mok, Byoung Chul Cho · 2017 · Lung Cancer
56. Tailoring inorganic nanoadjuvants towards next-generation vaccines
    Xia Li, Xiupeng Wang, Atsuo Ito · 2018 · Chemical Society Reviews
57. Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
    Ivo Buchhalter, Eugen Rempel, Volker Endris, Michael Allgäuer, Olaf Neumann, Anna‐Lena Volckmar, Martina Kirchner, Jonas Leichsenring, Amelie Lier, Moritz von Winterfeld et al. · 2018 · International Journal of Cancer
58. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
    Andrew B. Nixon, Kurt Alex Schalper, Ira Allen Jacobs, Shobha Potluri, I‐Ming Wang, Catherine Fleener · 2019 · Journal for ImmunoTherapy of Cancer
59. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang, Adebayo Ogunniyi, Meagan Spencer Barbee, Alexander Edward Dela Cruz Drilon · 2015 · Expert Review of Anticancer Therapy
60. Targeting Immune Checkpoints in Cancer Therapy
    Suzanne Louise Topalian · 2017 · JAMA
61. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
    Manuel Jorge Rodrigues, Lenha Mobuchon, Alexandre Houy, Alice Fiévet, Sophie Gardrat, Raymond L. Barnhill, Tatiana G. Popova, Vincent Servois, Aurore Rampanou, Aurore Mouton et al. · 2018 · Nature Communications
62. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade
    Lee P. Richman, Robert H. Vonderheide, Andrew J. Rech · 2019 · Cell Systems
63. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours
    Johansson, Peter A., Brooks, Kelly, Newell, Felicity, Palmer, Jane M., Wilmott, James S., Pritchard, Antonia L., Broit, Natasa, Wood, Scott, Carlino, Matteo S., Leonard, Conrad et al. · 2020 · Nature Communications
64. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
    Ilgen Mender, Anli Zhang, Zhenhua Ren, Chuanhui Han, Yafang Deng, Silvia Siteni, Huiyu Li, Jiankun Zhu, Aishwarya Vemula, Jerry W. Shay et al. · 2020 · Cancer Cell
65. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
    Fang, Douglas D., Tang, Qiuqiong, Kong, Yanhui, Wang, Qixin, Gu, Jiaxing, Fang, Xu, Zou, Peng, Rong, Tao, Wang, Jingwen, Yang, Dajun et al. · 2019 · Journal for ImmunoTherapy of Cancer
66. Inhibitory receptors as targets for cancer immunotherapy
    Meghan E. Turnis, Lawrence Peter Andrews, Dario A.A. Vignali · 2015 · European Journal of Immunology
67. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
    James W. Opzoomer, Dominika Sosnowska, Joanne E. Anstee, James F. Spicer, James N. Arnold · 2019 · Frontiers in Immunology
68. Cancer type-dependent correlations between TP53 mutations and antitumor immunity
    Lin Li, Mengyuan Li, Xiaosheng Wang · 2020 · DNA repair
69. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
    Kenneth K.W. To, Winnie Fong, William Chi Shing Cho · 2021 · Frontiers in Oncology
70. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
    Jing Huang, Lei Wang, Zhongyi Cong, Zohreh Amoozgar, Evgeny Kiner, Deyin Xing, Sandra Oršulić, Ursula A. Matulonis, Michael S. Goldberg · 2015 · Biochemical and Biophysical Research Communications
71. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
    David Liu, Philip H. Abbosh, Daniel Keliher, Brendan Michael Reardon, Diana Miao, Kent William Mouw, Amaro N Taylor-Weiner, Stephanie A. M. Wankowicz, G. Celine Han, Min Yuen Teo et al. · 2017 · Nature Communications
72. Genomics and emerging biomarkers for immunotherapy of colorectal cancer
    Jakob Nikolas Kather, Niels Halama, Dirk Jaeger · 2018 · Seminars in Cancer Biology
73. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity
    Jingcheng Wu, Wenzhe Wang, Jiucheng Zhang, Binbin Zhou, Wenyi Zhao, Zhixi Su, Xun Gu, Jian Wu, Zhan Mei Zhou, Shuqing Chen · 2019 · Frontiers in Immunology
74. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer
    Biagio Ricciuti, Gonzalo Recondo, Liam Flinn Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette Marie Sholl et al. · 2020 · Clinical Cancer Research
75. Colorectal cancer immunotherapy-Recent progress and future directions
    Wen Zhao, Lujia Jin, Peng Chen, Dingchang Li, Wenxing Gao, Guanglong Dong · 2022 · Cancer Letters
76. PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
    Menglei Jin, Jun Fang, Junwen Peng, Xintian Wang, Ping Xing, Kunpeng Jia, Jianming Hu, Danting Wang, Yuxin Ding, Xinyu Wang et al. · 2024 · Molecular Cancer
77. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
    Simpson, Rebecca C., Shanahan, Erin R., Scolyer, Richard A., Long, Georgina V. · 2023 · Nature Reviews Clinical Oncology
78. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
    Nadeem Riaz, Jonathan J. Havel, Sviatoslav M. Kendall, Vladimir Makarov, Logan A. Walsh, Alexis Desrichard, Nils Weinhold, Timothy An-thy Chan · 2016 · Nature Genetics
79. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
    Riki Okita, Ai Maeda, Katsuhiko Shimizu, Yuji Nojima, Shinsuke Saisho, Masao Nakata · 2017 · Cancer Immunology Immunotherapy
80. Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases
    Di Wang, Xiaohui Niu, Zhijie Wang, Chengli Song, Zhen Huang, Ke‐Neng Chen, Jianchun Duan, Hua Bai, Jiachen Xu, Jun Zhao et al. · 2018 · Cancer Research
81. Clinical utility of circulating tumor DNA for colorectal cancer
    Hiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, Hitoshi Zembutsu · 2019 · Cancer Science
82. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
    Xiaoying Sun, Raheleh Roudi, Ting Dai, Shangya Chen, Bin Fan, Hongjin Li, Yaqiong Zhou, Min Zhou, Bo Zhu, Chengqian Yin et al. · 2019 · BMC Cancer
83. Pathology and Classification of SCLC
    Maria Gabriela Raso, Neus Bota‐Rabassedas, Ignacio Ivan Wistuba · 2021 · Cancers
84. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
    Blanca Homet Moreno, Jesse Meir Zaretsky, Ángel García-Díaz, Jennifer Tsoi, Giulia Parisi, Lídia Robert, Katrina M. Meeth, Abibatou Ndoye, Marcus Bosenberg, Ashani T. Weeraratna et al. · 2016 · Cancer Immunology Research
85. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management
    Jules L. Derks, Noémie Leblay, Sylvie Lantuéjoul, Anne‐Marie C. Dingemans, Ernst‐Jan M. Speel, Lynnette Fernandez‐Cuesta · 2018 · Journal of Thoracic Oncology
86. Rational combinations of immunotherapy with radiotherapy in ovarian cancer
    Fernanda Gabriela Herrera, Melita B. Irving, Lana Elias Kandalaft, George Coukos · 2019 · The Lancet Oncology
87. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
    Alain Patrick Algazi, Chris Twitty, Katy K. Tsai, Mai Hope Le, Robert Hamilton Pierce, Erica Browning, Reneta Hermiz, David A. Canton, Donna Bannavong, Arielle Oglesby et al. · 2020 · Clinical Cancer Research
88. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
    Miller, A, Asmann, Y, Cattaneo, L, Braggio, E, Keats, J, Auclair, D, Lonial, S, The MMRF CoMMpass Network, Russell, S J, Stewart, A K · 2017 · Blood Cancer Journal
89. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes
    Feixiong Cheng, Junfei Zhao, Zhongming Zhao · 2015 · Briefings in Bioinformatics
90. The role of immune checkpoint inhibition in the treatment of ovarian cancer
    Stephanie L. Gaillard, Angeles Alvarez Secord, Bradley J. Monk · 2016 · Gynecologic Oncology Research and Practice
91. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo
    Zoë N Rogers, Christopher D. McFarland, Ian P. Winters, Santiago Naranjo, Chen-Hua Chuang, Dmitri A. Petrov, Monte M. Winslow · 2017 · Nature Methods
92. Immune checkpoint inhibitors in cancer therapy
    S. Eika, Liu Peng, Renato B. Baleeiro, R. Nicholas, Yuan Ming, Wang Yaohe · 2017 · Journal of Biomedical Research
93. Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
    Liu, Zilei, Li, Jie P., Chen, Mingkuan, Wu, Mengyao, Shi, Yujie, Li, Wei, Teijaro, John R., Wu, Peng · 2020 · Cell
94. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Devin C. Dressman, Antonios Papanicolau‐Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo et al. · 2018 · Journal for ImmunoTherapy of Cancer
95. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
    Rimas Vincas Lukas, Jordi Ahnert Rodon, Kevin P. Becker, Eric T. Wong, Kent C. Shih, Mehdi Touat, Marcella Fassò, Stuart Osborne, Luciana Lorena Molinero, Carol Elaine O'Hear et al. · 2018 · Journal of Neuro-Oncology
96. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
    Sangeetha S. Palakurthi, Mari Kuraguchi, Sima J. Zacharek, Enrique Zudaire, Wei Huang, Dennis M. Bonal, Jeffrey Liu, Abha Dhaneshwar, Kristin DePeaux, Martha R. Gowaski et al. · 2019 · Cancer Immunology Research
97. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
    Chan-Young Ock, Sehui Kim, Bhumsuk Keam, Miso Kim, Tae Min Kim, Jin-Ho Kim, Yoon Kyung Jeon, Ju‐Seog Lee, Seong Keun Kwon, Jeong Hun Hah et al. · 2016 · Oncotarget
98. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Davis Schollenberger, William Howard Sharfman, Janis Marie Taube · 2017 · Journal for ImmunoTherapy of Cancer
99. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
    Qiaohong Wang, Xia Wu · 2017 · International Immunopharmacology
100. The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
     Constantin N. Baxevanis, Sotirios P. Fortis, Sonia A. Perez · 2019 · Seminars in Cancer Biology